Barco Nv Earnings Call Highlights Mixed Yet Upbeat Outlook

Barco Nv (OTC) ((BCNAY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Barco Nv struck a cautiously upbeat tone on its latest earnings call, pointing to steady revenue growth, stronger profitability and a standout Entertainment division, even as Healthcare weakness, U.S. tariffs and currency headwinds weighed on results. Management framed 2025 as a year of tangible progress and strategic repositioning, but acknowledged that some recovery, especially in U.S. Healthcare, remains timing-dependent.

Revenue Growth

Barco reported full-year sales of EUR 964 million, an increase of 2% year-over-year on a reported basis and 4% at constant currency. Management highlighted that growth was broad-based but uneven, with particular strength in EMEA offset by softer trends in the Americas.

Profitability and EBITDA

EBITDA reached EUR 125 million, translating into a 13% margin for the year. Adjusting for one-offs, foreign exchange and tariff impacts, recurring EBITDA improved by roughly EUR 30 million, underscoring underlying operational progress despite external cost pressures.

Earnings Per Share and Capital Returns

Earnings per share climbed 20% year-over-year to EUR 0.85, benefiting from improved margins and capital efficiency. Barco returned about EUR 120 million to shareholders through dividends and completed share buybacks, and the Board is proposing a higher EUR 0.55 per-share dividend plus cancellation of around 6% of outstanding shares.

Entertainment Segment Outperformance

The Entertainment segment was the star performer, with sales up about 11% and profit growing 27%, powered by Cinema and Immersive Experience. Barco reported a cinema capture rate above 60%, more than 50 HDR systems installed in 2025 and over 100 in the 2026 pipeline, with HDR contracts totaling about EUR 89 million and a shift toward Cinema-as-a-Service that lifts lifetime value to 8–10 times a single projector sale.

Regional Strength in EMEA

The EMEA region delivered double-digit momentum, with sales and orders each advancing roughly 11%, providing a strong backbone for group growth. This regional performance helped offset weaker Americas activity and highlighted the benefits of Barco’s diversified geographic footprint.

Operational Discipline and Cost Control

Operating expenses were tightly managed, ending about 4% below the prior year as Barco leaned on automation and process optimization to protect margins. Research and development spending normalized to roughly 12.6% of sales after a heavy 2024 product development cycle, signaling a more balanced cost base while preserving innovation capacity.

Cash Generation and Balance Sheet Metrics

Free cash flow came in at EUR 57 million, about 6% of sales, underlining solid cash conversion from operations. The company closed the year with a net cash position of EUR 186 million, while holding inventories flat year-on-year, improving inventory turns to approximately 2.2 times and keeping days sales outstanding at 65 days.

Sustainability and Customer Metrics

Eco-labeled product revenues rose to 67%, up 8 percentage points year-over-year and ahead of Barco’s internal goal, showing that sustainability is feeding directly into the top line. Employee engagement improved to 67 and the Net Promoter Score climbed to 60, up about six points, reflecting positive customer feedback on product quality and after-sales service.

Healthcare Performance Weakness

Healthcare was the main drag, with EBITDA falling 22% to EUR 26.5 million and the margin slipping to 10.1%. Management cited slower U.S. orders tied to delayed government spending, tariff and FX impacts, and softer surgical renewals in the second half, and stressed that structural actions are underway to restore performance.

U.S. Market and Tariff/Currency Headwinds

Americas sales declined around 3% on an ex-currency basis, as Barco contended with a weaker dollar and tariff-related cost inflation. The company quantified roughly EUR 7 million in tariff impact and about EUR 8 million in FX effects versus prior-year comparables, with projection shipments singled out as particularly affected.

Order Visibility and Shorter Lead Times

Order intake at constant currency grew by less than 2% year-over-year and bookings occurred later in the cycle, compressing order-to-sales conversion times. Management explained that normalized supply chains and shorter lead times have shifted customer behavior to more “book-and-turn” patterns, which supports near-term revenue but reduces forward visibility.

Modality and Competitive Pressure in China

Barco described its modality business as increasingly commoditized, facing intense price competition from Chinese players. To respond, the company is moving modality ownership to its Suzhou hub in China, aiming to cut costs and sharpen competitiveness, but acknowledging that margins are under pressure and the business needs structural repositioning.

Margin Variability and Cautious Guidance

Investors pressed management on why strong divisional performance does not translate into a higher group margin target, given current momentum. Barco reaffirmed its medium-term goal of EUR 1.1 billion in revenue and a 15% EBITDA margin by 2028, but pointed to the timing of a Healthcare recovery and foreign-exchange exposure in the first half as reasons to maintain conservative group-level guidance.

Net Cash Reduction and Cash Uses

Net cash fell by about EUR 73 million over the year to EUR 186 million, largely due to shareholder distributions and continued investment. Management indicated that excess cash will now be prioritized for capital expenditure, factory upgrades and potential acquisitions, and that further share buybacks are paused for the time being.

Working Capital and Contract Effects

Working capital ticked up by roughly 1%, influenced partly by contracts in progress tied to Cinema-as-a-Service, which account for around EUR 10 million and weigh on working capital and free cash flow metrics. Barco aims to normalize working capital toward 12% over time, while recognizing that some investment needs and CaaS-related effects will remain in the model.

Segment-Specific Near-Term Risk in Surgical

Within Healthcare, the Surgical business faces a near-term air pocket after a strong first half, as key contracts expired and replacement cycles involve long design-in periods. Management cautioned that this creates a temporary headwind for revenue and margins heading into 2026, even though the underlying demand pipeline remains intact.

Forward-Looking Guidance

Looking ahead, Barco expects both revenue and EBITDA to grow in fiscal 2026 at constant currency, with the bulk of improvement weighted toward the second half and some FX pressure still likely in the first half. The company reaffirmed its 2028 targets of EUR 1.1 billion in sales, a 15% EBITDA margin and 15% recurring revenue, while emphasizing a strategic tilt from capex-heavy projector sales to software and OpEx-based recurring models to support future profitability.

Barco’s latest earnings call painted a picture of a company that is steadily improving its core metrics while reshaping its portfolio for more recurring, higher-margin business. Strong Entertainment and EMEA performances, disciplined cost control and solid cash generation provide a firm base, but sustained upside will depend on navigating Healthcare recovery, U.S. headwinds and competitive pressures without losing margin momentum.